INTRODUCTION

Schizophrenia (SCZ) is a debilitating psychiatric disorder characterized by positive (e.g. hallucinations)
and negative (e.g. avolition) symptoms, and cognitive deficits, with a global prevalence of up to 1·1%. 1 One-third of SCZ patients are non-responsive to standard anti-psychotic medications. 1 Bipolar disorder (BPD) is an affective disorder characterized by periods of mania and depression, with a lifetime prevalence of up to 4%. 2 Up to 37% of BPD patients are treatment-resistant to first-line mood-stabilizing drugs. 2 Major depressive disorder (MDD) is the most common psychiatric disorder worldwide with a 16·2% lifetime prevalence and poor treatment response in up to 30% of patients. 3 SCZ, BPD, and MDD have high heritability rates upwards of 0·85, 0·79, and 0·45, respectively. 4 Large concerted efforts to determine the causative genes for SCZ, BPD, and MDD through genome-wide association studies have identified numerous genes with only small effect sizes. [1] [2] [3] [4] These studies have focused on identifying common variants, with less attention being attributed to rare, more penetrant variants.
Though individually rare, genetic diseases are collectively common, with an estimated global prevalence of 1 in 100. 5 Often overlooked is that many genetic diseases are treatable, particularly inborn errors of metabolism (IEMs), a group of rare diseases that result from mutations in genes that encode proteins or enzymes along metabolic pathways. Although most IEMs are diagnosed in early childhood, there has been an increased recognition of late-or adult-onset IEMs that can present with psychiatric symptoms that are indistinguishable from primary psychiatric illnesses, such as SCZ; examples of such disorders are shown in supplementary Table 1 . 6 Significantly, identification of a genetic diagnosis in a psychiatric patient would reveal targeted management and, particularly with IEMs, specific treatments that could ameliorate the psychiatric symptoms and prevent onset of other systemic features of the diseases. To date, there have been several literature reviews and case studies suggesting the importance of investigating
IEMs as a primary factor in psychosis and SCZ (e.g. Nia et al. (2014) ). 6 Trakadis et al. (2017) recently reported a significant mild enrichment (odds ratios between 1·13-1·64) in an unselected group of 2545 adults with SCZ from the Database of Genotypes and Phenotypes of rare, presumed functional variants in several IEM genes, including NPC1 and NPC2 (associated with Niemann-Pick disease type C (NPC)), ATP7B (associated with Wilson disease (WD), and CBS (associated with homocystinuria (HOM)). 7 It is unclear how well the patient cohort was characterized, as well as how many of the identified rare variants are known to be associated with disease or how strongly they are predicted to be pathogenic. The authors suggest the need for a prospective study to document the prevalence of such IEMs in patients with psychosis.
Beyond the diagnosis of patients with IEMs to allow for targeted treatments, there is emerging evidence that heterozygous carriers for autosomal recessive IEMs can present with milder or limited phenotypes. 12, 13 Significantly, the neurological and psychiatric symptoms of a heterozygous ATP7B mutation carrier with acquired hepatocerebral degeneration, and normal copper and ceruloplasmin levels, were almost completely ameliorated by treatment with penicillamine, a copper-chelating agent commonly used in the treatment of WD.
14 The high heritability, heterogeneous symptomatology, and treatment resistance rates seen in SCZ, BPD, and MDD are suggestive of the involvement of intrinsic factors, such as underlying genetic disorders.
Recognition of the clinical findings that may be associated with carrier status for recessive disorders and the potential for targeted treatment further increase the impact of identifying pathogenic IEM variants in psychiatric patients.
In this study, we test the hypothesis that psychiatric populations are enriched for pathogenic variants associated with treatable genetic disorders by performing next-generation sequencing (NGS) in large cohorts of well-defined SCZ, BPD, and MDD patients for pathogenic variants in genes associated with four treatable IEMs, NPC, WD, HOM, and acute intermittent porphyria (AIP).
MATERIALS AND METHODS
Samples
A total of 2046 DNA samples from SCZ (n=1132, 100 with tardive dyskinesia), BPD (n=719), and MDD (n=195) patients were included in this study. Sample characteristics were described previously elsewhere. 15 Table 3 ).
Bioinformatic Analysis
Bioinformatic analysis was performed on the CAMH Specialized Computing Cluster with in-house scripts (refer to supplementary documents for details). Pathogenicity of sequence variants was interpreted according to American College of Medical Genetics and Genomics (ACMG) guidelines.
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Statistical Analysis
Statistical comparison of observed variant frequencies for NPC, WD, HOM, and AIP to expected frequencies based on general population carrier frequencies was performed using the exact binomial test, and comparison to the Genome Aggregation Database (gnomAD: http://gnomad.broadinstitute.org/)
whole-exome sequenced population (WES; n=123 136) was performed using the Fisher's exact test in R version 3·4·0. 18 Exon coverage and depth plots are available on the gnomAD website. The gnomAD consortium intends to release a non-psychiatric subset in the near future; this was not available at the time of our analysis nor a release date mentioned. Statistical comparison of treatment response in subjects with and without pathogenic variants was performed using the Fisher's exact test in R. All statistical test performed were 2-sided and all tests were Bonferroni corrected.
Protein Modelling of Variant Substitutions
Protein modelling was performed using the PyMOL Molecular Graphics System, Version 1·8
(Schrödinger LLC, USA). Protein Data Bank (PDB) protein structures 3JD8, 4L3V, and 3EQ1 were used to model eight unique predicted pathogenic variants within NPC1, CBS, and HMBS proteins, respectively. [19] [20] [21] The first, most likely, rotamer was chosen to depict the amino acid change. Protein modelling could not be performed for ATP7B and NPC2 variants due to a lack of complete protein structures in the PDB. Figure 1 summarizes the variants identified through bioinformatic analysis and validated by Sanger sequencing. Exon coverage and depth of all five genes sequenced averaged 400x per sample across all exons. A total of 1531 variants were identified in the five genes following filtration and annotation. Of these, 28 known pathogenic (22 missense, two missense leading to a stop gain, two splice, one insertion, and one deletion; Table 2 and supplementary Table 4 ), and 20 predicted pathogenic (one insertion leading to a stop loss, 19 missense; Table 3 and supplementary Table 5 ) variants were validated by Sanger sequencing. Notably, four known and one predicted pathogenic variants were found in the HMBS gene, strongly suggesting that the individuals carrying these variants are affected with AIP, an autosomal dominant disorder.
RESULTS
Variants Identified
Prevalence of Pathogenic Variants in Psychiatric Populations
The carrier frequencies for the autosomal recessive disorders NPC, WD, and HOM, and the predicted rate of individuals affected with AIP in our SCZ, BPD, and MDD cohorts are shown in Table 4 . Overall, NPC carrier rate was found to be marginally higher in the SCZ cohort (1·06%) compared to general population (95% CI, 0·006-0·019; p=0·336) and significantly higher than in the gnomAD population (95% CI, 1·704-4·829; p=5·24e-04) populations. Ethnicity-matched variant frequencies from the gnomAD WES cohort are shown in supplementary Table 5 for each of the predicted pathogenic variants; all variants were either absent or found at very low frequency. Additionally, two SCZ patients were found to have homozygous N931I likely pathogenic variant. The predicted affected rate of AIP was found to be significantly enriched across the entire cohort of SCZ, BPD, and MDD patients (0·24%) relative to the general (95% CI, 0·001-0·006; p=1·031e-10) and gnomAD (95% CI, 1·162-8·945; p=0·043) populations.
Protein Modelling
The protein locations of the known and predicted pathogenic variants identified in this study are shown in supplementary Figure 2 . Protein modelling results are shown in Table 3 for variants where analysis was possible. These predicted structural modifications to the NPC1, CBS, and HMBS proteins are shown in supplementary Figure 3 .
DISCUSSION
Our study used rigorous genetic and bioinformatic analysis, including Sanger sequencing validation of variants identified by NGS, stringent variant analysis parameters and protein modelling, to screen for pathogenic variants associated with selected treatable genetic diseases in well-defined psychiatric cohorts.
In our study, we found a significant enrichment of pathogenic gene variants associated with NPC in SCZ, and AIP across the entire cohort of SCZ, BPD, and MDD patients compared to both the expected frequencies based on general population prevalence and the gnomAD comparison population. The variant frequencies seen in the gnomAD cohort were higher than expected in the general population, likely due to the inclusion of individuals from psychiatric exome studies. There remains a significant enrichment of NPC and AIP pathogenic variants in our pure psychiatric cohort compared to the heterogeneous gnomAD population, potentially hinting at the extent of the impact of these IEM variants in the pathogenesis of the psychiatric disorders. The frequencies of WD and HOM pathogenic variants were similar to those expected in the general population, though there was an enrichment of WD carriers in the psychiatric cohort compared to the gnomAD population. Protein modelling for predicted pathogenic variants identified in NPC1, CBS, and HMBS demonstrated an overall disruption of polar bonds, and the majority of NPC1 and ATP7B variants are located in functional or conserved domains, providing substantial support for the likelihood of these variants being damaging to protein structure and function.
One of the major limitations of this study was the inability to perform adequate analysis of insertion and deletion variants due to the intrinsic limitations of the ION PROTON™ sequencing platform. The error rate of the sequencer in homopolymer DNA regions resulted in high false positive call rates for small insertions/deletions resulting in frameshift mutations. 22 Despite this, our study still demonstrated a significantly higher frequency of pathogenic variants in selected IEM genes in our psychiatric cohorts. This is highly suggestive that the prevalence of these rare disease variants in psychiatric populations is, in fact, much higher.
The NPC carrier rate identified in this study (0·83%), particularly in the SCZ cohort, was higher than that previously reported by Wassif et al. (2016) , who estimated a population carrier rate of 0·659% based on their predicted incidence rates of 1/92 104 and 1/2 858 998 for NPC1 and NPC2, respectively. 23 Their results were based on analysis of large exome data sets, with variants classified as pathogenic when predicted by at least two pathogenicity prediction algorithms used, while our analysis was based on more stringent criteria of pathogenic predictions by at least three algorithms, supporting the likelihood that the carrier rate is truly higher. Moreover, our NPC carrier frequency is likely to be an underestimation given the study limitations described. The estimated disease prevalence of NPC in our psychiatric cohort based on our detected carrier frequency is 0.002%, twice what is expected in the general population (0.001%). 24 Two patients in the study cohort were found to carry the likely pathogenic N931I variant in the homozygous state, potentially representing affected individuals. Available medical history was insufficient to determine the likelihood of these individuals being affected with NPC and follow-up with biochemical testing will need to be pursued. Nevertheless, along with the carrier rate seen, the data support that NPC gene variants are enriched in psychiatric patients. Individuals with NPC exhibit cholesterol disturbances that can negatively affect the homeostasis of myelinated axons, which are lipidrich and highly lipid-dependent brain structures, suggesting a possible mechanism by which NPC1 and NPC2 mutations could be contributing to mental illnesses.
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) mice show motor dysfunction, anxiety-like behaviour, and neurodegeneration, possibly through tau protein mechanisms, supporting the hypothesis that heterozygous NPC carrier states increase the risk for neuropsychiatric phenotypes. 26, 27 Miglustat, the only approved treatment for NPC, has been shown to lower total tau levels in the cerebrospinal fluid of NPC patients, suggesting the possibility that treatment of heterozygous NPC carriers with miglustat could improve neuropsychiatric symptoms and prevent further neurodegeneration. 28 Future studies as to the functional impact of being a heterozygous carrier for NPC variants will be of great interest in determining exact mechanisms for an association with psychiatric symptomatology. Biochemical assays in NPC carriers, such as by oxysterol or bile acid profiles, or filipin staining of fibroblasts, could be informative. Taken together, NPC should be considered more carefully in the psychiatric clinical setting, especially in patients with SCZ.
We did not detect any difference in carrier rate for WD in our cohort (0·98%) compared to the reported general population carrier rate (1·10%), or to the gnomAD population (0·94%). 29 There is some suggestion that heterozygous carriers for WD may accumulate copper in the basal ganglia, and that associated neuropsychiatric symptoms are responsive to first-line treatments used in WD. 14, 30 Given the potential for easily accessible and highly effective treatment, it is imperative that larger studies be undertaken to determine whether there is true enrichment of ATP7B pathogenic variants in psychiatric populations, particularly in patients with mood and affective disorders, which are more common in WD, as well as to further characterize the full spectrum of carrier phenotypes.
We did not detect any enrichment of HOM carriers within our psychiatric cohorts (0·20%) compared to an estimated carrier frequency of 0·45% using a conservative disease prevalence of 1 in 200 000 in the general population. 31 There was also no enrichment compared to the gnomAD population (0·11%). The true carrier prevalence in the general population for HOM remains unknown. There are currently no known phenotypic associations with heterozygous CBS mutation carriers; however, no large-scale studies have been performed to investigate this possibility. 1
The most significant enrichment seen in our study cohort was for pathogenic variants associated with AIP, with a frequency of 0·24% across the entire cohort of SCZ, BPD, and MDD patients compared to the general population frequency of 0·001% (95% CI, 0·001-0·006; p=1·031e-10) and gnomAD population frequency of 0·07% (95% CI, 1·162-8·945; p=0·043). 32 Other studies using biochemical screening have suggested a prevalence of up to 0.39% for AIP in psychiatric populations, though it is difficult to ascertain selection bias in some older studies. While biochemical confirmation of the genetic diagnosis will need to be sought for these patients, particularly those suspected to be affected with AIP, identification of an underlying genetic disorder reveals targeted therapy that can quickly and effectively alleviate current and future symptomatology. In addition, there is emerging evidence to suggest that heterozygous carriers for recessive disorders, such as NPC and WD, may exhibit milder or limited phenotypes. Identification of a genetic diagnosis, or carrier status for a genetic disease, in an individual has important implications for family planning and recurrence risks for family members.
Our study results provide proof of principle that pathogenic genetic variants associated with treatable African 80 (7) 37 (5) 13 (7) 130 (6) Eastern Asian 63 (6) 17 (2) 10 (5) 90 (4) South Asian 61 (5) 25 (4) 6 (3) 92 (5) Other 40 (4) 29 (4) 9 (5) 78 (4) 
